Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo

被引:44
|
作者
Wang, Hongbo [1 ,2 ]
Li, Hongyan [1 ,2 ]
Zuo, Minxin [1 ,2 ]
Zhang, Yi [1 ,2 ]
Liu, He [1 ,2 ]
Fang, Weishuo [2 ]
Chen, Xiaoguang [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Inst Mat Med, Dept Pharmacol, Beijing 100050, Peoples R China
[2] Peking Union Med Coll, Beijing 100050, Peoples R China
关键词
Lx2-32c; microtubule; cell cycle arrest; antitumor activity;
D O I
10.1016/j.canlet.2008.03.051
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lx2-32c, a novel taxane derivative, is a semisynthetic analogue from cephalomannine. Its antitumor activity in vivo and in vitro was investigated in this study. Lx2-32c was cytotoxic (IC50 = 1.7 +/- 1.6 nM) to various human tumor cell lines after 72 h incubation. In vitro it enhanced the rate of tubulin polymerization in a dose-dependent manner and induced the bundling of microtubule in BGC-823 cells with the mode similar to that of paclitaxel. As determined by flow cytometry, after either 12 or 24 h exposure, Lx2-32c caused BGC-823 cells G(2)/M phase arrest in a time- and dose-dependent manner. Moreover, we demonstrated that Lx2-32c had significant antitumor activity on BGC-823 (human gastric carcinoma) and A549 (human non-small cell lung carcinoma) xenograft in nude mice. These data suggest that Lx2-32c is a microtubule-stabilizing agent, which has significant antitumor activity in vitro and in vivo. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:89 / 97
页数:9
相关论文
共 50 条
  • [21] In vitro and in vivo antitumor activity of novel ceramide analogs
    Fogli, S
    Damesi, R
    Giovannetti, E
    Grossi, E
    Macchia, M
    Del Tacca, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 15 - 15
  • [22] Lx2-32c inhibits the formation of mammosphere from MDA-MB-231 cells and induces apoptosis involving in down-regulating FoxM1
    Cai, Pei
    Xiao, Zuoqi
    Pan, Tao
    Wen, Xiaoke
    Cao, Jianguo
    Ouyang, Bo
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 102 : 1176 - 1181
  • [23] Novel Sophoridine Derivatives Bearing Phosphoramide Mustard Moiety Exhibit Potent Antitumor Activities In Vitro and In Vivo
    Li, Dongdong
    Dai, Linlin
    Zhao, Xiumei
    Zhi, Shuang
    Shen, Hongsheng
    Yang, Zibo
    [J]. MOLECULES, 2018, 23 (08)
  • [24] In vitro and in vivo anticancer activities of a novel antibiotic
    Chen Xiaoxi
    [J]. AFRICAN JOURNAL OF BIOTECHNOLOGY, 2011, 10 (41): : 8137 - 8139
  • [25] 紫杉烷类衍生物Lx2-32c对人卵巢癌A2780细胞的抑制作用
    王洪波
    李洪燕
    方唯硕
    陈晓光
    [J]. 中国新药杂志, 2008, (10) : 833 - 836
  • [26] Design, Synthesis and in vitro Antitumor Activities of Novel Bivalent β-Carbolines
    Guo Liang
    Cao Rihui
    Fan Wenxi
    Gan Ziyun
    Ma Qin
    [J]. CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2016, 37 (06): : 1093 - 1099
  • [27] Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo
    Mi, Dazhao
    Li, Cheng
    Li, Yuzhan
    Yao, Mingyue
    Li, Yan
    Hong, Keyu
    Xie, Chengying
    Chen, Yihua
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
  • [28] In vitro and in vivo antitumor activity of novel ceramide analogs.
    Fogli, S
    Danesi, R
    Giovannetti, E
    Grossi, E
    Macchia, M
    Del Tacca, M
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4564S - 4564S
  • [29] Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo
    Spencer, Jeffrey R.
    Sendzik, Martin
    Oeh, Jason
    Sabbatini, Peter
    Dalrymple, Stacie A.
    Magill, Catherine
    Kim, Hyunjin M.
    Zhang, Penglie
    Squires, Neil
    Moss, Katherine G.
    Sukbuntherng, Juthamas
    Graupe, Doris
    Eksterowicz, John
    Young, Peter R.
    Myers, Andrew G.
    Green, Michael J.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (18) : 4884 - 4888
  • [30] A novel salvianolic acid A analog with resveratrol structure and its antioxidant activities in vitro and in vivo
    Qiu, Jin-Mei
    Qin, Chang-Feng
    Wu, Shen-Gen
    Ji, Tong-Ying
    Tang, Guo-Tao
    Lei, Xiao-Yong
    Cao, Xuan
    Xie, Zhi-Zhong
    [J]. DRUG DEVELOPMENT RESEARCH, 2021, 82 (01) : 108 - 114